GlassScriptPhysician profile
Emmalyn Newman
NPI 1407324593
$2,187.98
in general payments reported to CMS, 2019-2025
28 companies · $904 in 2025
The $904 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.90 · 2023: $229 · 2024: $1,000 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $333.60 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $274.11 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $231.81 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $188.30 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $171.30 | 2024-2025 | |
| Exact Sciences Corporation | $141.04 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $104.14 | 2024-2025 | |
| Shield Therapeutics INC | $82.87 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $76.25 | 2024 | |
| Dynavax Technologies Corporation | $76.13 | 2023-2025 | Heplisav-B |
| Sumitomo Pharma America, INC. | $63.46 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $48.86 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $44.46 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Dexcom, INC. | $43.49 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $31.63 | 2025 | Symbravo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $31.39 | 2025 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.62 | 2025 | Xifaxan |
| Amgen INC. | $26.88 | 2024 | Repatha, Otezla |
| Inspire Medical Systems, INC. | $22.77 | 2025 | Inspire |
| Abbott Laboratories | $21.75 | 2025 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $21.40 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.96 | 2025 | Jardiance |
| Acadia Pharmaceuticals INC | $19.83 | 2025 | Daybue |
| Novartis Pharmaceuticals Corporation | $19.35 | 2021 | |
| Tris Pharma INC | $17.85 | 2024 | Dyanavel Xr |
| Pulmonx Corporation | $16.32 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Bayer Healthcare Pharmaceuticals INC. | $14.57 | 2023 | |
| Xeris Pharmaceuticals, INC. | $13.84 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmalyn Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.